RU2005100783A

RU2005100783A - MITOTIC KINESINE INHIBITORS

Info

Publication number: RU2005100783A
Application number: RU2005100783/04A
Authority: RU
Inventors: Кеннет Л. АРРИНГТОН (US); Кеннет Л. Аррингтон; Пол Дж. КОУЛМАН (US); Пол Дж. Коулман; Кристофер Д. КОКС (US); Кристофер Д. КОКС; Марк Э. ФРЭЛИ (US); Марк Э. Фрэли; Роберт М. ГАРБАЧЧО (US); Роберт М. ГАРБАЧЧО; Джордж М. ХАРТМАН (US); Джордж М. ХАРТМАН; Уиль м Ф. ХОФФМАН (US); Уильям Ф. ХОФФМАН; Эдвард С. ТАСБЕР (US); Эдвард С. ТАСБЕР
Original assignee: Мерк энд Ко., Инк. (US); Мерк Энд Ко., Инк.
Priority date: 2002-06-14
Filing date: 2003-06-12
Publication date: 2005-07-20

Claims

1. The compound of formula I

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein

a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

n is 0 or 1;

r is 0 or 1;

s is 0 or 1;

u is 2, 3, 4 or 5;

the dashed line denotes an optional double bond, provided that one and only one double bond is present in said ring;

R ^{1 is} selected from

1) (C ₁ -C ₆ alkylene) _n (C = X) C ₁ -C ₁₀ alkyl,

2) (C ₁ -C ₆ alkylene) _n (C = X) aryl,

3) (C ₁ -C ₆ alkylene) _n (C = X) C ₂ -C ₁₀ alkenyl,

4) (C ₁ -C ₆ alkylene) _n (C = X) C ₂ -C ₁₀ alkynyl,

5) (C ₁ -C ₆ alkylene) _n (C = X) C ₃ -C ₈ cycloalkyl,

6) (C ₁ -C ₆ alkylene) _n (C = X) heterocyclyl,

7) (C ₁ -C ₆ alkylene) _n (C = X) NR ^C R ^{C '} ,

8) (C ₁ -C ₆ alkylene) _n SO ₂ NR ^C R ^{C '} ,

9) (C ₁ -C ₆ alkylene) _n SO ₂ C ₁ -C ₁₀ alkyl,

10) (C ₁ -C ₆ alkylene) _n SO ₂ C ₂ -C ₁₀ alkenyl,

11) (C ₁ -C ₆ alkylene) _n SO ₂ C ₂ -C ₁₀ alkynyl,

12) (C ₁ -C ₆ alkylene) _n SO ₂ aryl,

13) (C ₁ -C ₆ alkylene) _n SO ₂ heterocyclyl,

14) (C ₁ -C ₆ alkylene) _n SO ₂ -C ₃ -C ₈ cycloalkyl,

15) (C ₁ -C ₆ alkylene) _n P (= O) R ^d R ^{d '} ,

16) aryl,

17) heterocyclyl and

18) C ₁ -C ₁₀ alkyl,

wherein said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, alkylene, heteroaryl and heterocyclyl are optionally substituted with one or more substituents selected from R ¹⁰ ;

R ² and R ^{6 are} independently selected from

1) aryl,

2) C ₁ -C ₆ aralkyl,

3) C ₃ -C ₈ cycloalkyl, and

4) heterocyclyl,

wherein said aryl, cycloalkyl, aralkyl and heterocyclyl are optionally substituted with one or more substituents selected from R ¹⁰ ;

R ³ , R ⁴ , R ⁵ , R ⁷ , R ⁸ and R ^{9 are} independently selected from

1) H,

2) C ₁ -C ₁₀ alkyl,

3) aryl,

4) C ₂ -C ₁₀ alkenyl,

5) C ₂ -C ₁₀ alkynyl,

6) C ₁ -C ₆ perfluoroalkyl,

7) C ₁ -C ₆ aralkyl,

8) C ₃ -C ₈ cycloalkyl and

9) heterocyclyl,

wherein said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, aralkyl and heterocyclyl are optionally substituted with one or more substituents selected from R ¹⁰ ; or

R ⁴ and R ⁵ , or R ⁸ and R ⁹ attached to the same carbon atom, are combined to form - (CH ₂ ) _u -, where one of the carbon atoms is optionally substituted with a group selected from O, S (O) _m , —N (R ^a ) C (O) -, N (R ^b ) - and —N (COR ^a ) -;

R ^{10 is} independently selected from

1) (C = O) _a 0 _b C ₁ -C ₁₀ alkyl,

2) (C = O) _a O _b aryl,

3) C ₂ -C ₁₀ alkenyl,

4) C ₂ -C ₁₀ alkynyl,

5) (C = O) _a O _b heterocyclyl,

6) CO ₂ N,

7) halogen,

8) CN,

9) OH,

10) About _b C ₁ -C ₆ perfluoroalkyl,

11) O _a (C = O) _b NR ¹² R ¹³ ,

12) S (O) _m R ^a ,

13) S (O) ₂ NR ¹² R ¹³ ,

14) oxo,

15) SSS

16) (N = O) R ¹² R ¹³ or

17) (C = O) _a O _b C ₃ -C ₈ cycloalkyl,

wherein said alkyl, aryl, alkenyl, alkynyl, heterocyclyl and cycloalkyl are optionally substituted with one or more substituents selected from R ¹¹ ;

R ^{11 is} selected from

1) (C = O) _r O _S (C ₁ -C ₁₀ ) alkyl,

2) O _r (C ₁ -C ₃ ) perfluoroalkyl,

3) (C ₀ -C ₆ ) alkylene-S (O) _m R ^a ,

4) oxo,

5) OH

6) halogen,

7) CN,

8) (C = O) _r O _s (C ₂ -C ₁₀ ) alkenyl,

9) (C = O) _r O _s (C ₂ -C ₁₀ ) alkynyl,

10) (C = O) _r O _s (C ₃ -C ₆ ) cycloalkyl,

11) (C = O) _r O _s (C ₀ -C ₆ ) alkylene aryl,

12) (C = O) _r O _s (C ₀ -C ₆ ) alkyleneheterocyclyl,

13) (C = O) _r O _s (C ₀ -C ₆ ) alkylene-N (R ^b ) ₂ ,

14) C (O) R ^a ,

15) (C ₀ -C ₆ ) alkylene-CO ₂ R ^a ,

16) C (O) H,

17) (C ₀ -C ₆ ) alkylene-CO ₂ H,

18) C (O) N (R ^b ) ₂ ,

19) S (O) _m R ^a and

20) S (O) ₂ N (R ^b ) ₂ ,

wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl are optionally substituted with one, two or three substituents selected from R ^b , OH, (C ₁ -C ₆ ) alkoxy, halogen, CO ₂ H, CN, O ( C = O) C ₁ -C ₆ alkyl oxo and N (R ^b ) ₂ ;

R ¹² and R ^{13 are} independently selected from

1) H,

2) (C = O) O _b C ₁ -C ₁₀ alkyl,

3) (C = O) O _b C ₃ -C ₈ cycloalkyl,

4) (C = O) O _b aryl,

5) (C = O) O _b heterocyclyl,

6) C ₁ -C ₁₀ alkyl,

7) aryl,

8) C ₂ -C ₁₀ alkenyl,

9) C ₂ -C ₁₀ alkynyl,

10) heterocyclyl,

11) C ₃ -C ₈ cycloalkyl,

12) SO ₂ R ^a and

13) (C = O) NR ^b ₂ ,

wherein said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl and alkynyl are optionally substituted with one or more substituents selected from R ¹¹ ; or

R ¹² and R ¹³ may be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring, and optionally containing, in addition to nitrogen, one or two additional heteroatoms selected from N, O and S, wherein said monocyclic or bicyclic heterocycle is optionally substituted with one or more substituents selected from R ¹¹ ;

R ^{14 is} independently selected from

1) (C = O) _a O _b C ₁ -C ₁₀ alkyl,

2) (C = O) _a O _b aryl,

3) C ₂ -C ₁₀ alkenyl,

4) C ₂ -C ₁₀ alkynyl,

5) (C = O) _a O _b heterocyclyl,

6) CO ₂ H,

7) halo

8) CN,

9) OH,

10) O _b C ₁ -C ₆ perfluoroalkyl,

11) O _a (C = O) _b NR ¹² R ¹³ ,

12) S (O) _m R ^a ,

13) S (O) ₂ NR ¹² R ¹³ ,

14) oxo,

15) CHO,

16) (N = O) R ¹² R ¹³ or

17) (C = O) _a O _b C ₃ -C ₈ cycloalkyl,

R ^a represents (C ₁ -C ₆ ) alkylm, (C ₃ -C ₆ ) cycloalkyl, aryl or heterocyclyl, optionally substituted with one, two or three substituents selected from R ¹⁴ ;

R ^b represents H, (C ₁ -C ₆ ) alkyl, aryl, heterocyclyl, (C ₃ -C ₆ ) cycloalkyl, (C = O) OC ₁ -C ₆ alkyl, (C = O) C ₁ -C ₆ alkyl or S (O) ₂ R ^a optionally substituted with one, two or three substituents selected from R ¹⁴ ;

R ^c and R ^{c 'are} independently selected from H, (C ₁ -C ₆ ) alkyl, aryl, heterocyclyl and (C ₃ -C ₆ ) cycloalkyl, optionally substituted with one, two or three substituents selected from R ¹⁰ ; or

R ^c and R ^{c '} can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring, and optionally containing, in addition to nitrogen, one or two additional heteroatoms selected from N, O and S, wherein said monocyclic or bicyclic heterocycle is optionally substituted with one, two or three substituents selected from R ¹¹ ;

R ^d and R ^{d ′ are} independently selected from (C ₁ -C ₆ ) alkyl, (C ₁ -C ₆ ) alkoxy, and NR ^b ₂ ; or

R ^d and R ^{d '} can be taken together with the phosphorus to which they are attached to form a monocyclic heterocycle with a 5-7 membered ring, and optionally containing, in addition to phosphorus, one or two additional heteroatoms selected from NR ^e , O and S, wherein said monocyclic heterocycle is optionally substituted with one, two or three substituents selected from R ¹¹ ;

R ^{e is} selected from H and (C ₁ -C ₆ ) alkyl; and

X is selected from O, NR ^e, and S.

2. The compound according to claim 1 of formula I

or its pharmaceutically acceptable salt or stereoisomer, where

a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

n is 0 or 1;

r is 0 or 1;

s is 0 or 1;

u is 2, 3, 4 or 5;

R ^{1 is} selected from

1) (C ₁ -C ₆ alkylene) _n (C = X) C ₁ -C ₁₀ alkyl,

2) (C ₁ -C ₆ alkylene) _n (C = X) aryl,

3) (C ₁ -C ₆ alkylene) _n (C = X) C ₂ -C ₁₀ alkenyl,

4) (C ₁ -C ₆ alkylene) _n (C = X) C ₂ -C ₁₀ alkynyl,

5) (C ₁ -C ₆ alkylene) _n (C = X) C ₃ -C ₈ cycloalkyl,

6) (C ₁ -C ₆ alkylene) _n (C = X) heterocyclyl,

7) (C ₁ -C ₆ alkylene) _n (C = X) NR ^C R ^{C '} ,

8) (C ₁ -C ₆ alkylene) _n SO ₂ NR ^C R ^{C '} ,

9) (C ₁ -C ₆ alkylene) _n SO ₂ C ₁ -C ₁₀ alkyl,

10) (C ₁ -C ₆ alkylene) _n SO ₂ C ₂ -C ₁₀ alkenyl,

11) (C ₁ -C ₆ alkylene) _n SO ₂ C ₂ -C ₁₀ alkynyl,

12) (C ₁ -C ₆ alkylene) _n SO ₂ aryl,

13) (C ₁ -C ₆ alkylene) _n SO ₂ heterocyclyl,

14) (C ₁ -C ₆ alkylene) _n SO ₂ -C ₃ -C ₈ cycloalkyl,

15) (C ₁ -C ₆ alkylene) _n P (= O) R ^d R ^{d '} ,

16) aryl,

17) heterocyclyl and

18) C ₁ -C ₁₀ alkyl,

R ² and R ^{6 are} independently selected from

1) aryl,

2) C ₁ -C ₆ aralkyl,

3) C ₃ -C ₈ cycloalkyl, and

4) heterocyclyl,

R ³ , R ⁴ , R ⁵ , R ⁷ , R ⁸ and R ^{9 are} independently selected from

1) H,

2) C ₁ -C ₁₀ alkyl,

3) aryl,

4) C ₂ -C ₁₀ alkenyl,

5) C ₂ -C ₁₀ alkynyl,

6) C ₁ -C ₆ perfluoroalkyl,

7) C ₁ -C ₆ aralkyl,

8) C ₃ -C ₈ cycloalkyl and

9) heterocyclyl,

R ⁴ and R ⁵ , or R ⁸ and R ⁹ , attached to the same carbon atom, are combined to form - (CH ₂ ) _u -, where one of the carbon atoms is optionally substituted with a group selected from O, S (O) _m , —N (R ^a ) C (O) -, N (R ^b ) - and —N (COR ^a ) -;

R ^{10 is} independently selected from

1) (C = O) _a 0 _b C ₁ -C ₁₀ alkyl,

2) (C = O) _a O _b aryl,

3) C ₂ -C ₁₀ alkenyl,

4) C ₂ -C ₁₀ alkynyl,

5) (C = O) _a O _b heterocyclyl,

6) CO ₂ N,

7) halo

8) CN,

9) OH,

10) About _b C ₁ -C ₆ perfluoroalkyl,

11) O _a (C = O) _b NR ¹² R ¹³ ,

12) S (O) _m R ^a ,

13) S (O) ₂ NR ¹² R ¹³ ,

14) oxo,

15) SSS

16) (N = O) R ¹² R ¹³ or

17) (C = O) _a O _b C ₃ -C ₈ cycloalkyl,

R ^{11 is} selected from

1) (C = O) _r O _S (C ₁ -C ₁₀ ) alkyl,

2) O _r (C ₁ -C ₃ ) perfluoroalkyl,

3) (C ₀ -C ₆ ) alkylene-S (O) _m R ^a ,

4) oxo,

5) OH

6) halogen,

7) CN,

8) (C = O) _r O _s (C ₂ -C ₁₀ ) alkenyl,

9) (C = O) _r O _s (C ₂ -C ₁₀ ) alkynyl,

10) (C = O) _r O _s (C ₃ -C ₆ ) cycloalkyl,

11) (C = O) _r O _s (C ₀ -C ₆ ) alkylene aryl,

12) (C = O) _r O _s (C ₀ -C ₆ ) alkyleneheterocyclyl,

13) (C = O) _r O _s (C ₀ -C ₆ ) alkylene-N (R ^b ) ₂ ,

14) C (O) R ^a ,

15) (C ₀ -C ₆ ) alkylene-CO ₂ R ^a ,

16) C (O) H,

17) (C ₀ -C ₆ ) alkylene-CO ₂ H,

18) C (O) N (R ^b ) ₂ ,

19) S (O) _m R ^a and

20) S (O) ₂ N (R ^b ) ₂ ,

wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl are optionally substituted with one, two or three substituents selected from R ^b , OH, (C ₁ -C ₆ ) alkoxy, halogen, CO ₂ H, CN, O ( C = O) C ₁ -C ₆ alkyl, oxo and N (R ^b ) ₂ ;

R ¹² and R ^{13 are} independently selected from

1) H,

2) (C = O) O _b C ₁ -C ₁₀ alkyl,

3) (C = O) O _b C ₃ -C ₈ cycloalkyl,

4) (C = O) O _b aryl,

5) (C = O) O _b heterocyclyl,

6) C ₁ -C ₁₀ alkyl,

7) aryl,

8) C ₂ -C ₁₀ alkenyl,

9) C ₂ -C ₁₀ alkynyl,

10) heterocyclyl,

11) C ₃ -C ₈ cycloalkyl,

12) SO ₂ R ^a and

13) (C = O) NR ^b ₂ ,

R ¹² and R ¹³ can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring, and optionally containing, in addition to nitrogen, one or two additional heteroatoms selected from N, O and S, wherein said monocyclic or bicyclic heterocycle is optionally substituted with one or more substituents selected from R ¹¹ ;

R ^a represents (C ₁ -C ₆ ) alkyl, (C ₃ -C ₆ ) cycloalkyl, aryl or heterocyclyl;

R ^b represents H, (C ₁ -C ₆ ) alkyl, aryl, heterocyclyl, (C ₃ -C ₆ ) cycloalkyl, (C = O) OC ₁ -C ₆ alkyl, (C = O) C ₁ -C ₆ alkyl or S (O) ₂ R ^a ;

R ^c and R ^{c '} can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring, and optionally containing, in addition to nitrogen, one or two additional heteroatoms selected from N, O and S, wherein said monocyclic or bicyclic heterocycle is optionally substituted with one, two or three substituents selected from R ¹¹ ;

R ^d and R ^{d ′ are} independently selected from: (C ₁ -C ₆ ) alkyl, (C ₁ -C ₆ ) alkoxy, and NR ^b ₂ ; or

R ^{e is} selected from H and (C ₁ -C ₆ ) alkyl; and

X is selected from O, NR ^e, and S.

3. The compound according to claim 2 of formula I

or its pharmaceutically acceptable salt or stereoisomer, where

a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

n is 0 or 1;

r is 0 or 1;

s is 0 or 1;

u is 2, 3, 4 or 5;

R ^{1 is} selected from

1) (C ₁ -C ₆ alkylene) _n (C = X) C ₁ -C ₁₀ alkyl,

2) (C ₁ -C ₆ alkylene) _n (C = X) aryl,

3) (C ₁ -C ₆ alkylene) _n (C = X) C ₂ -C ₁₀ alkenyl,

4) (C ₁ -C ₆ alkylene) _n (C = X) C ₂ -C ₁₀ alkynyl,

5) (C ₁ -C ₆ alkylene) _n (C = X) C ₃ -C ₈ cycloalkyl,

6) (C ₁ -C ₆ alkylene) _n (C = X) heterocyclyl,

7) (C ₁ -C ₆ alkylene) _n (C = X) NR ^C R ^{C '} ,

8) (C ₁ -C ₆ alkylene) _n SO ₂ NR ^C R ^{C '} ,

9) (C ₁ -C ₆ alkylene) _n SO ₂ C ₁ -C ₁₀ alkyl,

10) (C ₁ -C ₆ alkylene) _n SO ₂ C ₂ -C ₁₀ alkenyl,

11) (C ₁ -C ₆ alkylene) _n SO ₂ C ₂ -C ₁₀ alkynyl,

12) (C ₁ -C ₆ alkylene) _n SO ₂ aryl,

13) (C ₁ -C ₆ alkylene) _n SO ₂ heterocyclyl,

14) (C ₁ -C ₆ alkylene) _n SO ₂ -C ₃ -C ₈ cycloalkyl,

15) (C ₁ -C ₆ alkylene) _n P (= O) R ^d R ^{d '} ,

16) aryl,

17) heterocyclyl and

18) C ₁ -C ₁₀ alkyl;

R ² and R ^{6 are} independently selected from

1) aryl,

2) C ₁ -C ₆ aralkyl,

3) C ₃ -C ₈ cycloalkyl, and

4) heterocyclyl,

R ³ , R ⁴ , R ⁵ , R ⁷ , R ⁸ and R ^{9 are} independently selected from

1) H,

2) C ₁ -C ₁₀ alkyl,

3) aryl,

4) C ₂ -C ₁₀ alkenyl,

5) C ₂ -C ₁₀ alkynyl,

6) C ₁ -C ₆ perfluoroalkyl,

7) C ₁ -C ₆ aralkyl,

8) C ₃ -C ₈ cycloalkyl and

9) heterocyclyl,

R ^{10 is} independently selected from

1) (C = O) _a 0 _b C ₁ -C ₁₀ alkyl,

2) (C = O) _a O _b aryl,

3) C ₂ -C ₁₀ alkenyl,

4) C ₂ -C ₁₀ alkynyl,

5) (C = O) _a O _b heterocyclyl,

6) CO ₂ N,

7) halogen,

8) CN,

9) OH,

10) About _b C ₁ -C ₆ perfluoroalkyl,

11) O _a (C = O) _b NR ¹² R ¹³ ,

12) S (O) _m R ^a ,

13) S (O) ₂ NR ¹² R ¹³ ,

14) oxo,

15) SSS

16) (N = O) R ¹² R ¹³ , or

17) (C = O) _a O _b C ₃ -C ₈ cycloalkyl,

R ^{11 is} selected from

1) (C = O) _r O _S (C ₁ -C ₁₀ ) alkyl,

2) O _r (C ₁ -C ₃ ) perfluoroalkyl,

3) (C ₀ -C ₆ ) alkylene-S (O) _m R ^a ,

4) oxo,

5) OH

6) halo

7) CN,

8) (C = O) _r O _s (C ₂ -C ₁₀ ) alkenyl,

9) (C = O) _r O _s (C ₂ -C ₁₀ ) alkynyl,

10) (C = O) _r O _s (C ₃ -C ₆ ) cycloalkyl,

11) (C = O) _r O _s (C ₀ -C ₆ ) alkylene aryl,

12) (C = O) _r O _s (C ₀ -C ₆ ) alkyleneheterocyclyl,

13) (C = O) _r O _s (C ₀ -C ₆ ) alkylene-N (R ^b ) ₂ ,

14) C (O) R ^a ,

15) (C ₀ -C ₆ ) alkylene-CO ₂ R ^a ,

16) C (O) H,

17) (C ₀ -C ₆ ) alkylene-CO ₂ H,

18) C (O) N (R ^b ) ₂ ,

19) S (O) _m R ^a and

20) S (O) ₂ N (R ^b ) ₂ ,

R ¹² and R ^{13 are} independently selected from

1) H,

2) (C = O) O _b C ₁ -C ₁₀ alkyl,

3) (C = O) O _b C ₃ -C ₈ cycloalkyl,

4) (C = O) O _b aryl,

5) (C = O) O _b heterocyclyl,

6) C ₁ -C ₁₀ alkyl,

7) aryl,

8) C ₂ -C ₁₀ alkenyl,

9) C ₂ -C ₁₀ alkynyl,

10) heterocyclyl,

11) C ₃ -C ₈ cycloalkyl,

12) SO ₂ R ^a and

13) (C = O) NR ^b ₂ ,

R ^c and R ^{c 'are} independently selected from H, (C ₁ -C ₆ ) alkyl, aryl, heterocyclyl and (C ₃ -C ₆ ) cycloalkyl; or

R ^{e is} selected from H and (C ₁ -C ₆ ) alkyl; and

X is selected from O, NR ^e, and S.

4. The compound according to claim 2 of formula II

or its pharmaceutically acceptable salt or stereoisomer, where

a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

n is 0 or 1;

r is 0 or 1;

s is 0 or 1;

the dashed line indicates an optional double bond, provided that one and only one double bond is present in said ring;

R ^{1 is} selected from

1) (C ₁ -C ₆ alkylene) _n (C = O) C ₁ -C ₁₀ alkyl,

2) (C ₁ -C ₆ alkylene) _n (C = O) aryl,

3) (C ₁ -C ₆ alkylene) _n (C = O) C ₂ -C ₁₀ alkenyl,

4) (C ₁ -C ₆ alkylene) _n (C = O) C ₂ -C ₁₀ alkynyl,

5) (C ₁ -C ₆ alkylene) _n (C = O) C ₃ -C ₈ cycloalkyl,

6) (C ₁ -C ₆ alkylene) _n (C = O) heterocyclyl,

7) (C ₁ -C ₆ alkylene) _n (C = O) NR ^C R ^{C '} ,

8) (C ₁ -C ₆ alkylene) _n SO ₂ NR ^C R ^{C '} ,

9) (C ₁ -C ₆ alkylene) _n SO ₂ C ₁ -C ₁₀ alkyl,

10) (C ₁ -C ₆ alkylene) _n SO ₂ aryl,

11) (C ₁ -C ₆ alkylene) _n SO ₂ heterocyclyl,

12) (C ₁ -C ₆ alkylene) _n SO ₂ -C ₃ -C ₈ cycloalkyl,

13) (C ₁ -C ₆ alkylene) _n P (= O) R ^d R ^{d '} ,

14) aryl,

15) heterocyclyl and

16) C ₁ -C ₁₀ alkyl,

R ² and R ^{6 are} independently selected from

1) aryl,

2) C ₁ -C ₆ aralkyl,

3) C ₃ -C ₈ cycloalkyl, and

4) heterocyclyl,

R ³ , R ⁴ , and R ^{8 are} independently selected from

1) H,

2) C ₁ -C ₁₀ alkyl,

3) aryl,

4) C ₂ -C ₁₀ alkenyl,

5) C ₂ -C ₁₀ alkynyl,

6) C ₁ -C ₆ perfluoroalkyl,

7) C ₁ -C ₆ aralkyl,

8) C ₃ -C ₈ cycloalkyl and

9) heterocyclyl,

R ^{10 is} independently selected from

1) (C = O) _a 0 _b C ₁ -C ₁₀ alkyl,

2) (C = O) _a O _b aryl,

3) C ₂ -C ₁₀ alkenyl,

4) C ₂ -C ₁₀ alkynyl,

5) (C = O) _a O _b heterocyclyl,

6) CO ₂ N,

7) halogen,

8) CN,

9) OH,

10) About _b C ₁ -C ₆ perfluoroalkyl,

11) O _a (C = O) _b NR ¹² R ¹³ ,

12) S (O) _m R ^a ,

13) S (O) ₂ NR ¹² R ¹³ ,

14) oxo,

15) SSS

16) (N = O) R ¹² R ¹³ or

17) (C = O) _a O _b C ₃ -C ₈ cycloalkyl,

wherein said alkyl, aryl, alkenyl, alkynyl, heterocyclyl and cycloalkyl are optionally substituted with one, two or three substituents selected from R ¹¹ ;

R ^{11 is} selected from

1) (C = O) _r O _S (C ₁ -C ₁₀ ) alkyl,

2) O _r (C ₁ -C ₃ ) perfluoroalkyl,

3) oxo,

4) OH,

5) halogen,

6) CN,

7) (C ₂ -C ₁₀ ) alkenyl,

8) (C ₂ -C ₁₀ ) alkynyl,

9) (C = O) _r O _s (C ₃ -C ₆ ) cycloalkyl,

10) (C = O) _r O _s (C ₀ -C ₆ ) alkylene aryl,

11) (C = O) _r O _s (C ₀ -C ₆ ) alkyleneheterocyclyl,

12) (C = O) _r O _s (C ₀ -C ₆ ) alkylene-N (R ^b ) ₂ ,

13) C (O) R ^a ,

14) (C ₀ -C ₆ ) alkylene-CO ₂ R ^a ,

15) C (O) H,

16) (C ₀ -C ₆ ) alkylene-CO ₂ H,

17) C (O) N (R ^b ) ₂ ,

18) S (O) _m R ^a and

19) S (O) ₂ N (R ^b ) ₂

R ¹² and R ^{13 are} independently selected from

1) H,

2) (C = O) O _b C ₁ -C ₁₀ alkyl,

3) (C = O) O _b C ₃ -C ₈ cycloalkyl,

4) (C = O) O _b aryl,

5) (C = O) O _b heterocyclyl,

6) C ₁ -C ₁₀ alkyl,

7) aryl,

8) C ₂ -C ₁₀ alkenyl,

9) C ₂ -C ₁₀ alkynyl,

10) heterocyclyl,

11) C ₃ -C ₈ cycloalkyl,

12) SO ₂ R ^a and

13) (C = O) NR ^b ₂ ,

wherein said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl and alkynyl are optionally substituted with one, two or three substituents selected from R ¹¹ ; or

R ¹² and R ¹³ can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring, and optionally containing, in addition to nitrogen, one or two additional heteroatoms selected from N, O and S, wherein said monocyclic or bicyclic heterocycle is optionally substituted with one, two or three substituents selected from R ¹¹ ;

R ^c and R ^{c 'are} independently selected from H, (C ₁ -C ₆ ) alkyl, aryl, heterocyclyl and (C ₃ -C ₆ ) cycloalkyl, or R ^c and R ^c' can be taken together with the nitrogen to which they attached, with the formation of a monocyclic or bicyclic heterocycle with 5-7 members in each ring, and optionally containing, in addition to nitrogen, one or two additional heteroatoms selected from N, O and S, where the specified monocyclic or bicyclic heterocycle is optionally substituted by one, two or three substituents selected from R ¹¹ ;

R ^{e is} selected from H and (C ₁ -C ₆ ) alkyl.

5. The compound of formula III

or its pharmaceutically acceptable salt or stereoisomer, where

a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

r is 0 or 1;

s is 0 or 1;

R ^{1 is} selected from

1) (C = O) C ₁ -C ₁₀ alkyl,

2) (C = O) aryl,

3) (C = O) C ₂ -C ₁₀ alkenyl,

4) (C = O) C ₂ -C ₁₀ alkynyl,

5) (C = O) C ₃ -C ₈ cycloalkyl,

6) (C = O) heterocyclyl,

7) (C = O) NR ^C R ^{C '} ,

8) SO ₂ NR ^C R ^{C '} ,

9) SO ₂ C ₁ -C ₁₀ alkyl,

10) SO ₂ -aryl,

11) SO ₂ heterocyclyl,

12) SO ₂ —C ₃ —C ₈ cycloalkyl; and

13) P (= O) R ^d R ^{d '} ,

wherein said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heteroaryl and heterocyclyl are optionally substituted with one or more substituents selected from R ¹⁰ ;

R ² selected from

1) aryl,

2) C ₁ -C ₆ aralkyl,

3) C ₃ -C ₈ cycloalkyl and

4) heterocyclyl,

R ³ , R ⁴ and R ^{8 are} independently selected from

1) H,

2) C ₁ -C ₁₀ alkyl,

3) aryl,

4) C ₂ -C ₁₀ alkenyl,

5) C ₂ -C ₁₀ alkynyl,

6) C ₁ -C ₆ perfluoroalkyl,

7) C ₁ -C ₆ aralkyl,

8) C ₃ -C ₈ cycloalkyl and

9) heterocyclyl,

wherein said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, aralkyl and heterocyclyl are optionally substituted with one or more substituents selected from R ¹⁰ ;

R ^{10 is} independently selected from

1) (C = O) _a 0 _b C ₁ -C ₁₀ alkyl,

2) (C = O) _a O _b aryl,

3) C ₂ -C ₁₀ alkenyl,

4) C ₂ -C ₁₀ alkynyl,

5) (C = O) _a O _b heterocyclyl,

6) CO ₂ N,

7) halogen,

8) CN,

9) OH,

10) About _b C ₁ -C ₆ perfluoroalkyl,

11) O _a (C = O) _b NR ¹² R ¹³ ,

12) S (O) _m R ^a ,

13) S (O) ₂ NR ¹² R ¹³ ,

14) oxo,

15) SSS

16) (N = O) R ¹² R ¹³ or

17) (C = O) _a O _b C ₃ -C ₈ cycloalkyl,

R ^{10 '} represents a halogen;

R ^{11 is} selected from

1) (C = O) _r O _S (C ₁ -C ₁₀ ) alkyl,

2) O _r (C ₁ -C ₃ ) perfluoroalkyl,

3) oxo,

4) OH,

5) halogen,

6) CN,

7) (C ₂ -C ₁₀ ) alkenyl,

8) (C ₂ -C ₁₀ ) alkynyl,

9) (C = O) _r O _s (C ₃ -C ₆ ) cycloalkyl,

10) (C = O) _r O _s (C ₀ -C ₆ ) alkylene aryl,

11) (C = O) _r O _s (C ₀ -C ₆ ) alkyleneheterocyclyl,

12) (C = O) _r O _s (C ₀ -C ₆ ) alkylene-N (R ^b ) ₂ ,

13) C (O) R ^a ,

14) (C ₀ -C ₆ ) alkylene-CO ₂ R ^a ,

15) C (O) H,

16) (C ₀ -C ₆ ) alkylene-CO ₂ H and

17) C (O) N (R ^b ) ₂ ,

18) S (O) _m R ^a and

19) S (O) ₂ N (R ^b ) ₂ ,

wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heterocyclyl are optionally substituted with one, two or three substituents selected from R ^b , OH, (C ₁ -C ₆ ) alkoxy, halogen, CO ₂ H, CN, O (C = O) C ₁ -C ₆ alkyl, oxo and N (R ^b ) ₂ ;

R ¹² and R ^{13 are} independently selected from

1) H,

2) (C = O) O _b C ₁ -C ₁₀ alkyl,

3) (C = O) O _b C ₃ -C ₈ cycloalkyl,

4) (C = O) O _b aryl,

5) (C = O) O _b heterocyclyl,

6) C ₁ -C ₁₀ alkyl,

7) aryl,

8) C ₂ -C ₁₀ alkenyl,

9) C ₂ -C ₁₀ alkynyl,

10) heterocyclyl,

11) C ₃ -C ₈ cycloalkyl,

12) SO ₂ R ^a and

13) (C = O) NR ^b ₂ ,

R ^d and R ^{d ′ are} independently selected from (C ₁ -C ₆ ) alkyl, (C ₁ -C ₆ ) alkoxy, and NR ^b ₂ , or

R ^d and R ^{d '} can be taken together with phosphorus to which they are attached to form a monocyclic heterocycle with a 5-7 membered ring, and optionally containing, in addition to phosphorus, one or two additional heteroatoms selected from NR ^e , O and S wherein said monocyclic heterocycle is optionally substituted with one, two or three substituents selected from R ¹¹ ; and

R ^{e is} selected from H and (C ₁ -C ₆ ) alkyl.

6. The compound according to claim 4 of formula IV

or its pharmaceutically acceptable salt or stereoisomer, where

a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

r is 0 or 1;

s is 0 or 1;

R ^{1 is} selected from

1) (C = O) C ₁ -C ₁₀ alkyl,

2) (C = O) aryl,

3) (C = O) C ₃ -C ₈ cycloalkyl,

4) (C = O) heterocyclyl,

5) (C = O) NR ^C R ^{C '} ,

6) (C = S) NR ^C R ^{C '} ,

7) SO ₂ NR ^C R ^{C '} ,

8) SO ₂ C ₁ -C ₁₀ alkyl,

9) SO ₂ -aryl and

10) SO ₂ -heterocyclyl,

wherein said alkyl, aryl, cycloalkyl and heterocyclyl are optionally substituted with one or more substituents selected from R ¹⁰ ;

R ² selected from

1) aryl,

2) C ₁ -C ₆ aralkyl,

3) C ₃ -C ₈ cycloalkyl, and

4) heterocyclyl,

R ³ , R ⁴ and R ^{8 are} independently selected from

1) H,

2) C ₁ -C ₁₀ alkyl, and

3) C ₁ -C ₆ perfluoroalkyl,

R ^{6 is} selected from

1) aryl,

2) C ₁ -C ₆ aralkyl,

3) C ₃ -C ₈ cycloalkyl, and

4) heterocyclyl,

R ^{10 is} independently selected from

1) (C = O) _a 0 _b C ₁ -C ₁₀ alkyl,

2) (C = O) _a O _b aryl,

3) C ₂ -C ₁₀ alkenyl,

4) C ₂ -C ₁₀ alkynyl,

5) (C = O) _a O _b heterocyclyl,

6) CO ₂ N,

7) halogen,

8) CN,

9) OH,

10) About _b C ₁ -C ₆ perfluoroalkyl,

11) O _a (C = O) _b NR ¹² R ¹³ ,

12) S (O) _m R ^a ,

13) S (O) ₂ NR ¹² R ¹³ ,

14) oxo,

15) SSS

16) (N = O) R ¹² R ¹³ or

17) (C = O) _a O _b C ₃ -C ₈ cycloalkyl,

R ^{11 is} selected from

1) (C = O) _r O _S (C ₁ -C ₁₀ ) alkyl,

2) O _r (C ₁ -C ₃ ) perfluoroalkyl,

3) oxo,

4) OH,

5) halogen,

6) CN,

7) (C ₂ -C ₁₀ ) alkenyl,

8) (C ₂ -C ₁₀ ) alkynyl,

9) (C = O) _r O _s (C ₃ -C ₆ ) cycloalkyl,

10) (C = O) _r O _s (C ₀ -C ₆ ) alkylene aryl,

11) (C = O) _r O _s (C ₀ -C ₆ ) alkyleneheterocyclyl,

12) (C = O) _r O _s (C ₀ -C ₆ ) alkylene-N (R ^b ) ₂ ,

13) C (O) R ^a ,

14) (C ₀ -C ₆ ) alkylene-CO ₂ R ^a ,

15) C (O) H,

16) (C ₀ -C ₆ ) alkylene-CO ₂ H,

17) C (O) N (R ^b ) ₂ ,

18) S (O) _m R ^a and

19) S (O) ₂ N (R ^b ) ₂

R ¹² and R ^{13 are} independently selected from

1) H,

2) (C = O) O _b C ₁ -C ₁₀ alkyl,

3) (C = O) O _b C ₃ -C ₈ cycloalkyl,

4) (C = O) O _b aryl,

5) (C = O) O _b heterocyclyl,

6) C ₁ -C ₁₀ alkyl,

7) aryl,

8) C ₂ -C ₁₀ alkenyl,

9) C ₂ -C ₁₀ alkynyl,

10) heterocyclyl,

11) C ₃ -C ₈ cycloalkyl,

12) SO ₂ R ^a and

13) (C = O) NR ^b ₂ ,

R ^{a is} independently selected from (C ₁ -C ₆ ) alkyl, (C ₃ -C ₆ ) cycloalkyl, aryl, and heterocyclyl;

R ^{b is} independently selected from H, (C ₁ -C ₆ ) alkyl, aryl, heterocyclyl, (C ₃ -C ₆ ) cycloalkyl, (C = O) OC ₁ -C ₆ alkyl, (C = O) C ₁ -C ₆ alkyl or S (O) ₂ R ^a ; and

R ^c and R ^{c '} can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring, and optionally containing, in addition to nitrogen, one or two additional heteroatoms selected from N, O and S, wherein said monocyclic or bicyclic heterocycle is optionally substituted with one, two or three substituents selected from R ¹¹ .

7. The compound according to claim 4 or its pharmaceutically acceptable salt or stereoisomer, and

R ^{1 is} selected from

1) (C = O) NR ^C R ^{C '} ,

2) SO ₂ NR ^C R ^{C '} ,

3) SO ₂ C ₁ -C ₁₀ alkyl,

wherein said alkyl is optionally substituted with one, two or three substituents selected from R ¹⁰ ;

R ² selected from

1) aryl and

2) heteroaryl,

wherein said aryl and heteroaryl are optionally substituted with one or more substituents selected from R ¹⁰ ;

R ³ , R ⁴ and R ^{8 are} independently selected from

1) H,

2) C ₁ -C ₁₀ alkyl,

wherein said alkyl is optionally substituted with one or more substituents selected from R ¹⁰ ; and

R ^{6 is} selected from

1) aryl and

2) heterocyclyl,

wherein said alkyl, aryl and heterocyclyl are optionally substituted with one or more substituents selected from R ¹⁰ ; and

R ¹⁰ , R ¹¹ , R ¹² , R ¹³ , R ^a , R ^b , R ^c , and R ^{c ′} are as just described above.

8. The compound according to claim 7, or a pharmaceutically acceptable salt or stereoisomer thereof, in which R ² and R ^{6 are} independently selected from phenyl or pyridyl optionally substituted with one or two substituents selected from R ¹⁰ ; and

R ¹ , R ³ , R ⁴ and R ⁸ are as described in claim 7.

9. The compound of claim 7, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R ² is phenyl optionally substituted with one or two substituents selected from R ¹⁰ ; and

R ¹ , R ³ , R ⁴ , R ⁶ and R ⁸ are as described in claim 7.

10. The compound according to claim 5 of formula V

where a is 0 or 1;

b is 0 or 1;

m is 0, 1 or 2;

r is 0 or 1;

s is 0 or 1;

R ^{1 is} selected from

1) (C = O) C ₁ -C ₁₀ alkyl,

2) (C = O) aryl,

3) (C = O) C ₃ -C ₈ cycloalkyl,

4) (C = O) heterocyclyl,

5) (C = O) NR ^C R ^{C '} ,

6) (C = S) NR ^C R ^{C '} ,

7) SO ₂ NR ^C R ^{C '} ,

8) SO ₂ C ₁ -C ₁₀ alkyl,

9) SO ₂ -aryl, and

10) SO ₂ -heterocyclyl,

R ² selected from

1) aryl,

2) C ₁ -C ₆ aralkyl,

3) C ₃ -C ₈ cycloalkyl, and

4) heterocyclyl,

R ³ , R ⁴ and R ^{8 are} independently selected from

1) H,

2) C ₁ -C ₁₀ alkyl, and

3) C ₁ -C ₆ perfluoroalkyl,

wherein said alkyl is optionally substituted with one or more substituents selected from R ¹⁰ ;

R ^{10 is} independently selected from

1) (C = O) _a 0 _b C ₁ -C ₁₀ alkyl,

2) (C = O) _a O _b aryl,

3) C ₂ -C ₁₀ alkenyl,

4) C ₂ -C ₁₀ alkynyl,

5) (C = O) _a O _b heterocyclyl,

6) CO ₂ N,

7) halogen,

8) CN,

9) OH,

10) About _b C ₁ -C ₆ perfluoroalkyl,

11) O _a (C = O) _b NR ¹² R ¹³ ,

12) S (O) _m R ^a ,

13) S (O) ₂ NR ¹² R ¹³ ,

14) oxo,

15) SSS

16) (N = O) R ¹² R ¹³ or

17) (C = O) _a O _b C ₃ -C ₈ cycloalkyl,

R ^{10 ′} is halogen;

R ^{11 is} selected from

1) (C = O) _r O _S (C ₁ -C ₁₀ ) alkyl,

2) O _r (C ₁ -C ₃ ) perfluoroalkyl,

3) oxo,

4) OH,

5) halogen,

6) CN,

7) (C ₂ -C ₁₀ ) alkenyl,

8) (C ₂ -C ₁₀ ) alkynyl,

9) (C = O) _r O _s (C ₃ -C ₆ ) cycloalkyl,

10) (C = O) _r O _s (C ₀ -C ₆ ) alkylene aryl,

11) (C = O) _r O _s (C ₀ -C ₆ ) alkyleneheterocyclyl,

12) (C = O) _r O _s (C ₀ -C ₆ ) alkylene-N (R ^b ) ₂ ,

13) C (O) R ^a ,

14) (C ₀ -C ₆ ) alkylene-CO ₂ R ^a ,

15) C (O) H,

16) (C ₀ -C ₆ ) alkylene-CO ₂ H,

17) C (O) N (R ^b ) ₂ ,

18) S (O) _m R ^a and

19) S (O) ₂ N (R ^b ) ₂

R ¹² and R ^{13 are} independently selected from

1) H,

2) (C = O) O _b C ₁ -C ₁₀ alkyl,

3) (C = O) O _b C ₃ -C ₈ cycloalkyl,

4) (C = O) O _b aryl,

5) (C = O) O _b heterocyclyl,

6) C ₁ -C ₁₀ alkyl,

7) aryl,

8) C ₂ -C ₁₀ alkenyl,

9) C ₂ -C ₁₀ alkynyl,

10) heterocyclyl,

11) C ₃ -C ₈ cycloalkyl,

12) SO ₂ R ^a and

13) (C = O) NR ^b ₂ ,

R ^c and R ^{c 'are} independently selected from: H, (C ₁ -C ₆ ) alkyl, aryl, heterocyclyl and (C ₃ -C ₆ ) cycloalkyl; or

11. The compound according to claim 1, selected from the group including

4- (2-chloro-5-fluorophenyl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(+) - 4- (2,5-difluorophenyl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(-) - 4- (2,5-difluorophenyl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrol-1-carboxamide;

4- (5-chloro-2-fluorophenyl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2-fluorophenyl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2-fluoro-5-methylphenyl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (5-bromo-2-fluorophenyl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4 - {[4- (5-chloro-2-fluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} morpholine;

4 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} morpholine;

N, N-dimethyl-2,4-diphenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

3- [2-fluoro-5- (trifluoromethyl) phenyl] -N, N-dimethyl-5-phenyl-2,3-dihydro-1H-pyrrole-1-carboxamide;

2- (3-fluorophenyl) -4- (2,5-difluorophenyl) -N, N-dimethyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (4-fluorophenyl) -N, N-dimethyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (2-fluorophenyl) -N, N-dimethyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

2- (3-bromophenyl) -4- (2,5-difluorophenyl) -N, N-dimethyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

2- (3-aminophenyl) -4- (2,5-difluorophenyl) -N, N-dimethyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-methylphenyl) -N, N-dimethyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (5-chloro-2-fluorophenyl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -1- (methylsulfonyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -1- (ethylsulfonyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -2-phenyl-1- (propylsulfonyl) -2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -1- (isopropylsulfonyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

4- (5-chloro-2-fluorophenyl) -1- (methylsulfonyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

4- (5-chloro-2-fluorophenyl) -1- (isopropylsulfonyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

4- (2-fluoro-5-methylphenyl) -1- (isopropylsulfonyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

2 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] sulfonyl} ethanamine;

2 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] sulfonyl} -N, N-dimethylethanamine;

1-acetyl-4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

4- (2-chloro-5-fluorophenyl) -1-pivaloyl-2-phenyl-2,5-dihydro-1H-pyrrole;

4- (2-chloro-5-fluorophenyl) -1-isobutyryl-2-phenyl-2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -1- (2,2-dimethylpropanoyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-methyl-1-oxopropan-2-ol;

1- [4- (5-chloro-2-fluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-methyl-1-oxopropan-2-ol;

1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-methyl-1-oxopropan-2-amine;

4- (2-fluoro-5-isocyanophenyl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2-phenyl-1- (trifluoroacetyl) -2,5-dihydro-1H-pyrrole;

4- (5-chloro-2-fluorophenyl) -2-phenyl-1- (trifluoroacetyl) -2,5-dihydro-1H-pyrrole;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2-methylpropylamine;

(1R) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2-methylpropylamine;

4- (2,5-difluorophenyl) -2-phenyl-1-L-prolyl-2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -2-phenyl-1-D-prolyl-2,5-dihydro-1H-pyrrole;

(4R) -4 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -1,3-thiazolidine;

methyl (3S) -3-amino-4- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -4-oxobutanoate;

(4S) -4-amino-5- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -5-oxopentanamide;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -3- (methylthio) propylamine;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -3- (methylsulfonyl) propylamine;

(2S) -2 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} piperidine;

(1S) -1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} pentylamine;

(1S) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxo-1- (thien-2-ylmethyl) ethylamine ;

4 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -1,1-dioxotetrahydro-2H-thiopyran-4-ylamine;

(2S) -1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N-methyl-1-oxopropan-2-amine;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} propylamine;

(1S) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxo-1-phenylethanamine;

3- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3-oxopropan-1-amine;

(1S, 2S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2-methylbutylamine;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} butylamine;

(1S) -1-cyclopropyl-2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethanamine;

1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} cyclopropanamine;

1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -1-oxopropan-2-amine;

(1S) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -1-methyl-2-oxoethylamine;

(1S) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxo-1- (pyridin-2-ylmethyl) ethylamine ;

(1S) -1-cyclohexyl-2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethanamine;

(1S) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -1- (4-iodobenzyl) -2-oxoethylamine;

(1S) -1-benzyl-2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethylamine;

4 - {(2S) -2-amino-3- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3-oxopropyl} phenol;

(3S) -3 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -1,2,3,4-tetrahydroisoquinoline;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -3-phenylpropylamine;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -3-methylbutylamine;

(1S) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxo-1- (pyridin-3-ylmethyl) ethylamine ;

1 - [(2S) -azetidin-2-ylcarbonyl] -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

(3S) -3-amino-4- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -4-oxobutanamide;

4- (2,5-difluorophenyl) -1 - [(2S) -2,5-dihydro-1H-pyrrol-2-ylcarbonyl] -2-phenyl-2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -1 - [(2-methylazetidin-2-yl) carbonyl] -2-phenyl-2,5-dihydro-1H-pyrrole;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2,2-dimethylpropylamine;

methyl (4S) -4-amino-5- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -5-oxopentanoate;

4- (2,5-difluorophenyl) -2-phenyl-1 - {[(2S, 3S) -2-phenylpyrrolidin-3-yl] carbonyl} -2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -2-phenyl-1 - [(5-phenylpyrrolidin-3-yl) carbonyl] -2,5-dihydro-1H-pyrrole;

(2S) -2-amino-3- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3-oxopropan-1-ol;

(2R, 3S) -3-amino-4- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -4-oxobutan-2-ol;

(1S) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -1- (methoxymethyl) -2-oxoethylamine;

4- (2,5-difluorophenyl) -2-phenyl-1- (pyrrolidin-3-ylcarbonyl) -2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -2-phenyl-1 - [(3-phenylpyrrolidin-3-yl) acetyl] -2,5-dihydro-1H-pyrrole;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -3,3-difluoropropylamine;

(1S) -3- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3-oxo-1-phenylpropan-1-amine;

4- (2,5-difluorophenyl) -2-phenyl-1 - [(4S) -4-phenyl-L-prolyl] -2,5-dihydro-1H-pyrrole;

1- {2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl} cyclohexanamine;

2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethanamine;

4 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} piperidin-4-amine;

(1S, 3R) -3 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} cyclopentanamine;

(1R, 4S) -4 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} cyclopent-2-en-1-amine;

(1S, 4R) -4 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} cyclopent-2-en-1-amine;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} but-3-ynylamine;

(1R) -3- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3-oxo-1-phenylpropan-1-amine;

3 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2-phenylpiperidine;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} but-3-enylamine;

(2S) -3- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- (methylamino) -3-oxopropan-1-ol;

(3R, 5S) -5 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} pyrrolidin-3-ol;

(1S) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxo-1- (1,3-thiazol-4 -ylmethyl) ethylamine;

(1R) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} but-3-enylamine;

(2S) -1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N, 3-dimethyl-1-oxobutane-2-amine;

(2S) -1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N, 4-dimethyl-1-oxopentan-2-amine;

(1S) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -1 - [(1-methyl-1H-imidazole-4- il) methyl] -2-oxoethylamine;

4- (2,5-difluorophenyl) -1- (N ~ 6 ~ -formyl-L-lysyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

(2S, 3S) -1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N, 3-dimethyl-1-oxopentan-2- amine;

(1S) -1- (cyclohexylmethyl) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethylamine;

(1S) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -1- (1H-indol-3-ylmethyl) -2- oxoethylamine;

(1S) -2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -1- (isocyanomethyl) -2-oxoethylamine;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -3,3-dimethylbutylamine;

1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2,3-dimethyl-1-oxobutan-2-amine;

1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} cyclohexanamine;

1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} cyclopentanamine;

(1S) -3- (benzyloxy) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} propylamine;

1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} cyclopent-3-en-1-amine;

(1S) -1-cyclopentyl-2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethanamine;

4- (2,5-difluorophenyl) -1- (2-methylpropyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

1- [4- (5-chloro-2-fluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-methyl-1-oxopropan-2-amine;

(1S) -1 - {[4- (5-chloro-2-fluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2-methylpropylamine;

(1S) -2- [4- (5-chloro-2-fluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -1-cyclopropyl-2-oxoethanamine;

(1S, 2S) -1 - {[4- (5-chloro-2-fluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2-methylbutylamine;

(1S) -1 - {[4- (5-chloro-2-fluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} pentylamine;

(1S) -1 - {[4- (5-chloro-2-fluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -3,3-dimethylbutylamine;

(1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2,2-dimethylpropylamine;

(1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2-methylpropylamine;

(1S) -1-cyclohexyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethanamine;

(1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} but-3-enylamine;

(1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} but-3-ynylamine;

(1S) -1-benzyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethylamine;

(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethanamine;

1 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-methyl-1-oxopropan-2-amine;

(1S) -1 - {[(2S) -4- (5-chloro-2-fluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2,2-dimethylpropylamine ;

(1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} pentylamine;

(1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -3-methylbutylamine;

(1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -3,3-dimethylbutylamine;

1-cyclopropyl-3 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3-oxopropan-1-amine;

(1S) -2 - [(2S) -4- (5-chloro-2-fluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -1-cyclopropyl-2-oxoethanamine;

(1S) -1 - {[(2S) -4- (5-chloro-2-fluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2-methylpropylamine;

(1S, 2S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2-methylbutylamine;

4- (5-chloro-2-fluorophenyl) -2- (3-hydroxyphenyl) -1- (2-methylalanyl) -2,5-dihydro-1H-pyrrole;

(2S) -4- (5-chloro-2-fluorophenyl) -2- (3-hydroxyphenyl) -1- (2-methylalanyl) -2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -1-L-valyl-2,5-dihydro-1H-pyrrole;

4- (5-chloro-2-fluorophenyl) -2- (3-hydroxyphenyl) -1-L-valyl-2,5-dihydro-1H-pyrrole;

(2S) -4- (5-chloro-2-fluorophenyl) -2- (3-hydroxyphenyl) -1-L-valyl-2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -1- (2-methylalanyl) -2,5-dihydro-1H-pyrrole;

3- [1 - [(2S) -2-amino-2-cyclopropylethanoyl] -4- (5-chloro-2-fluorophenyl) -2,5-dihydro-1H-pyrrol-2-yl] phenol;

4- (5-chloro-2-fluorophenyl) -2- (3-hydroxyphenyl) -1-L-isoleucyl-2,5-dihydro-1H-pyrrole;

4- (5-chloro-2-fluorophenyl) -2- (3-hydroxyphenyl) -1-L-norleucyl-2,5-dihydro-1H-pyrrole;

(2S) -4- (5-chloro-2-fluorophenyl) -2- (3-hydroxyphenyl) -1- (3-methyl-L-valyl) -2,5-dihydro-1H-pyrrole;

(2S) -4- (2,5-difluorophenyl) -N-methyl-2-phenyl-N-piperidin-4-yl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (2,5-difluorophenyl) -N-methyl-2-phenyl-N- (piperidin-4-ylmethyl) -2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (5-chloro-2-fluorophenyl) -N-methyl-2-phenyl-N - [(3R) -pyrrolidin-3-yl] -2,5-dihydro-1H-pyrrole-1- carboxamide;

(2S) -4- (5-chloro-2-fluorophenyl) -N-methyl-2-phenyl-N-piperidin-4-yl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (5-chloro-2-fluorophenyl) -N-methyl-2-phenyl-N - [(3S) -pyrrolidin-3-yl] -2,5-dihydro-1H-pyrrole-1- carboxamide;

(2S) -4- (2,5-difluorophenyl) -N-methyl-2-phenyl-N-pyrrolidin-3-yl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (2,5-difluorophenyl) -N-methyl-N - [(3S) -1-methylpyrrolidin-3-yl] -2-phenyl-2,5-dihydro-1H-pyrrole-1- carboxamide;

(2S) -4- (2,5-difluorophenyl) -N-methyl-N - [(3R) -1-methylpyrrolidin-3-yl] -2-phenyl-2,5-dihydro-1H-pyrrole-1- carboxamide;

(2S) -4- (2,5-difluorophenyl) -N-methyl-N - [(1-methyl-5-oxopyrrolidin-2-yl) methyl] -2-phenyl-2,5-dihydro-1H-pyrrole -1-carboxamide;

(2S) -4- (2,5-difluorophenyl) -N- (1,3-dioxolan-2-ylmethyl) -N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (2,5-difluorophenyl) -N-methyl-2-phenyl-N-tetrahydrofuran-3-yl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -N- (1-allylpiperidin-4-yl) -4- (2,5-difluorophenyl) -N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

allyl 4 - [{[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} (methyl) amino] piperidine-1-carboxylate ;

allyl 4 - {[{[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} (methyl) amino] methyl} piperidine- 1-carboxylate;

(2S) -4- (2,5-difluorophenyl) -N-methyl-N- (1-methylpiperidin-4-yl) -2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -N-methyl-N- (1-methylpiperidin-3-yl) methyl] -2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -N-methyl-2-phenyl-N- (pyridin-3-ylmethyl) -2,5-dihydro-1H-pyrrole-1-carboxamide;

N-benzyl-4- (2,5-difluorophenyl) -N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -N-methyl-N - [(1-methyl-1H-pyrazol-4-yl) methyl] -2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide ;

4- (2,5-difluorophenyl) -N- [2- (dimethylamino) ethyl] -N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -N- (2-hydroxyethyl) -N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -N-isobutyl-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -N-methyl-2-phenyl-N- (2-pyridin-2-yl-ethyl) -2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -N- (2-methoxyethyl) -N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -N- (2,3-dihydroxypropyl) -N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -N-methyl-2-phenyl-N- (2-phenylethyl) -2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2-phenyl-N-propyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (5-chloro-2-fluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N-piperidin-4-yl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N-piperidin-4-yl-2,5-dihydro-1H-pyrrole-1-carboxamide;

1-acetyl-4- (2,5-difluorophenyl) -2-methyl-2-phenyl-2,5-dihydro-1H-pyrrole;

(2S) -1- [4- (2,5-difluorophenyl) -2-methyl-2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3-methyl-1-oxobutan-2- amine;

(2S) -4- (2,5-difluorophenyl) -N, N, 2-trimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (5-chloro-2-fluorophenyl) -N, N, 2-trimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (5-chloro-2-fluorophenyl) -2-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (5-chloro-2-fluorophenyl) -N-ethyl-2-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -1 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3,3-dimethyl-1-oxobutane- 2-ol;

(2S) -1 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3-methyl-1-oxobutan-2- ol;

(2S, 3S) -1 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3-methyl-1-oxopentan- 2-ol;

1 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -1-oxohexan-2-ol;

(2S) -1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -1-oxo-3-phenylpropan-2-ol;

(2S) -1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -4-methyl-1-oxopentan-2-ol;

(1S) -1-cyclohexyl-2- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethanol;

(2S) -1- [4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3,3-dimethyl-1-oxobutan-2-ol;

N-1 - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} -N-2, N-2-dimethylglycinamide;

N-1 - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} -N-2-methylglycinamide;

N-1 - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} glycinamide;

N-1 - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} -2-methylalaninamide;

N-1 - {(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl} glycinamide;

N-1 - {(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl} -N-2, N-2-dimethylglycinamide;

N-1 - {(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl} -N-2, N-2-dimethylglycinamide, N-oxide;

N-1 - {(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl} -2-methylalaninamide;

N-1 - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} -N-2-, N-2-dimethylglycinamide, N-oxide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -2-pyrrolidin-1-yl-acetamide;

2-azetidin-1-yl-N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrole- 1-yl] -2-oxoethyl} acetamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -2-morpholin-4-yl-acetamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -2-piperazin-1-yl-acetamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -2- (4-methylpiperazin-1-yl) acetamide;

2-azetidin-1-yl-N - {(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H- pyrrol-1-yl] -2-oxoethyl} acetamide;

N - {(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} -2-pyrrolidin-1-yl-acetamide;

N - {(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} -2-piperidin-1-yl-acetamide;

N - {(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} -2-morpholin-4-yl-acetamide;

N-1 - {(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl} -N-2- (2-hydroxyethyl) glycinamide;

N - {(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} -2- (4-methylpiperazin-1-yl) acetamide;

N-1 - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} -N-2-isopropylglycinamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } acetamide;

N-1 {(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] - 2-oxoethyl} -N-2-ethylglycinamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -2-hydroxyacetamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } piperazine-1-carboxamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -N'-piperidin-4-ylurea;

4-amino-N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl} piperidine-1-carboxamide;

N- (2-aminoethyl) -N '- {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrole -1-yl] -2-oxoethyl} urea;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -N '- (3-morpholin-4-ylpropyl) urea;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -N '- [2- (dimethylamino) ethyl] urea;

2-azetidin-1-yl-N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrole- 1-yl] -2-oxoethyl} ethanesulfonamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -2- (isopropylamino) ethanesulfonamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -2-pyrrolidin-1-yl-ethanesulfonamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -2-morpholin-4-yl-ethanesulfonamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -2-piperazin-1-yl-ethanesulfonamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -2- (4-methylpiperazin-1-yl) ethanesulfonamide;

N- (tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] acetamide;

2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N-isopropylacetamide;

(2S) -1- (2-azetidin-1-yl-2-oxoethyl) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

(2S) -4- (2,5-difluorophenyl) -1- (2-oxo-2-pyrrolidin-1-yl-ethyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

4 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] acetyl} morpholine;

1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] acetyl} piperazine;

1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] acetyl} -4-methylpiperazine;

2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N-isopropylbutanamide;

4- {2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] butanoyl} morpholine;

2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N-ethylacetamide;

N-cyclobutyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] acetamide;

2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N-ethylpropanamide;

N-cyclobutyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] propanamide;

2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N-methylpropanamide;

2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N-isopropylpropanamide;

N- (tert-butyl) -2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] propanamide;

4- {2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] propanoyl} morpholine;

(3S) -3-amino-4 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N-ethyl-2, 2-dimethyl-4-oxobutanamide;

(3S) -3-amino-4 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2,2-dimethyl- 4-oxo-N-piperidin-4-ylbutanamide;

(3S) -3-amino-4 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2,2-dimethyl- 4-oxobutanoic acid;

(3S) -3-amino-4 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N, N, 2, 2-tetramethyl-4-oxobutanamide;

(1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2,2-dimethyl-3 oxo-3-piperazin-1-ylpropylamine;

(3S) -3-amino-4 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N-isopropyl-2, 2-dimethyl-4-oxobutanamide;

(3S) -3-amino-4 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N, 2,2- trimethyl-4-oxobutanamide;

(3R) -3-amino-4 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N, N, 2, 2-tetramethyl-4-oxobutanamide;

(3R) -3-amino-4 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2,2-dimethyl- 4-oxobutanoic acid;

(1R) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2,2-dimethyl-3 oxo-3-piperazin-1-ylpropylamine;

2 - ({(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] - 2-oxoethyl} amino) -N-ethylacetamide;

2 - ({(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] - 2-oxoethyl} amino) -N-methylacetamide;

2 - ({(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] - 2-oxoethyl} amino) -N, N-dimethylacetamide;

2 - ({(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] - 2-oxoethyl} amino) -N-methyl-N-ethylacetamide;

2 - ({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethyl} amino) -N-methylacetamide;

2 - ({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethyl} amino) -N-ethylacetamide;

2 - ({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethyl} amino) -N, N-dimethylacetamide;

2 - ({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethyl} amino) -N-isopropylacetamide;

2 - ({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethyl} amino) -N-ethyl-N-methylacetamide;

2 - ({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethyl} amino) -N, N-diethylacetamide;

(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxo-N- (2-oxo-2-pyrrolidin-1-yl-ethyl) ethanamine;

(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N- (2-morpholine -4-yl-2-oxoethyl) -2-oxoethanamine;

1 - [({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} amino) acetyl] piperidin-4-ol;

(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N- [2- ( 4-methylpiperazin-1-yl) -2-oxoethyl] -2-oxoethanamine;

(1S) -N- (2-azetidin-1-yl-2-oxoethyl) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro -1H-pyrrol-1-yl] -2-oxoethanamine;

(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N- [2- ( 1,1-dioxidothiomorpholin-4-yl) -2-oxoethyl] -2-oxoethanamine;

(1S) -N- [2- (4-acetylpiperazin-1-yl) -2-oxoethyl] -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2 5-dihydro-1H-pyrrol-1-yl] -2-oxoethanamine;

(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N- (2 morpholin-4-yl-2-oxoethyl) -2-oxoethanamine;

(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxo- N- (2-oxo-2-pyrrolidin-1-yl-ethyl) ethanamine;

2 - ({(1S) -1-tert-butyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] - 2-oxoethyl} amino) -N-isopropylacetamide;

2- (dimethylamino) ethyl (1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] - 2-oxoethyl carbamate;

1-methylpiperidin-4-yl (S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl carbamate;

(2S) -4-cyclopropyl-N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4-cyclopentyl-N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl 4-methylpiperazine -1-carboxylate;

1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] 2-oxoethyl-2-morpholin-4-yl-ethyl carbamate ;

N - [({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2 -oxoethyl} hydroxy) carbonyl] glycine;

(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl 1-methylpiperidine -4-ylcarbamate;

(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethylmethyl (1- methylpiperidin-4-yl) carbamate;

(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl-4- dimethylamino) piperidine-1-carboxylate;

tert-butyl (2S) -4- (2-chloro-5-fluoropyrimidin-4-yl) -2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxylate;

(2S) -4- (5-fluoro-2-methylpyrimidin-4-yl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (2-chloro-5-fluoropyrimidin-4-yl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (4-chloro-5-methylpyrimidin-2-yl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (6-chloropyrimidin-4-yl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (2-chloropyrimidin-4-yl) -N, N-dimethyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -N, N-dimethyl-4- (4-methylpyridin-3-yl) -2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -N, N-dimethyl-2-phenyl-4- (1,3-thiazol-2-yl) -2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -N, N-dimethyl-2-phenyl-4- (1,3-thiazol-4-yl) -2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -N, N-dimethyl-2-phenyl-4- (1,2-thiazol-5-yl) -2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N, N-dimethyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N, N-dimethyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (2,5-difluorophenyl) -N- (2-hydroxyethyl) -N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

N - {[4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -N-methyl-beta-alanine;

methyl N - {[4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -N-methyl-beta-alaninate;

4 - {[4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -2,5-dihydro-1H-pyrrol-1-yl] acetyl} morpholin-4-yl;

3 - [(2S) -4- (2,5-difluorophenyl) -1- (2-hydroxy-2-methylpropanoyl) -2,5-dihydro-1H-pyrrol-2-yl] phenol;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N, N-dimethyl-2,5-dihydro-1H-pyrrole-1-sulfonamide;

3- [4- (2,5-difluorophenyl) -1- (methylsulfonyl) -2,5-dihydro-1H-pyrrol-2-yl] phenol;

3- [4- (2,5-difluorophenyl) -1- (morpholin-4-ylcarbonyl) -2,5-dihydro-1H-pyrrol-2-yl] phenol;

3- [4- (2,5-difluorophenyl) -1- (2,2-dimethylpropanoyl) -2,5-dihydro-1H-pyrrol-2-yl] phenol;

(2S) -4- (2,5-difluorophenyl) -1 - [(methylsulfonyl) acetyl] -2-phenyl-2,5-dihydro-1H-pyrrole;

(2S) -4- (2,5-difluorophenyl) -2-phenyl-1 - [(phenylsulfonyl) acetyl] -2,5-dihydro-1H-pyrrole;

3 - [(2S) -1 - [(2S) -2-cyclopropyl-2-hydroxyethanoyl] -4- (2,5-difluorophenyl) -2,5-dihydro-1H-pyrrol-2-yl] phenol;

3 - {(2S) -4- (2,5-difluorophenyl) -1 - [(2S) -2-hydroxy-3,3-dimethylbutanoyl] -2,5-dihydro-1H-pyrrol-2-yl} phenol ;

(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethanol;

(2S) -4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N-tetrahydrofuran-3-yl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N- (2-methoxyethyl) -N-methyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

(2S) -4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N-tetrahydro-2H-pyran-4-yl-2,5-dihydro-1H-pyrrole-1- carboxamide;

3 - [(2S) -4- (2,5-difluorophenyl) -1- (piperidin-1-ylcarbonyl) -2,5-dihydro-1H-pyrrol-2-yl] phenol;

4- (2,5-difluorophenyl) -N- [1- (2-fluoroethyl) piperidin-4-yl] -2- (3-hydroxyphenyl) -N-methyl-2,5-dihydro-1H-pyrrole-1 β-carboxamide;

4 - [{[4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -2,5-dihydro-1H-pyrrol-1-yl] carbonyl} (methyl) amino] piperidinium trifluoroacetate;

2 - [{[4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -2,5-dihydro-1H-pyrrol-1-yl] carbonyl} (methyl) amino] ethyl 4-methylpiperazin-1 β-carboxylate;

3- {4- (2,5-difluorophenyl) -1 - [(4-methylpiperazin-1-yl) carbonyl] -2,5-dihydro-1H-pyrrol-2-yl} phenol;

2 - [{[4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -2,5-dihydro-1H-pyrrol-1-yl] carbonyl} (methyl) amino] ethyl morpholine-4-carboxylate ;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N - [(1-methyl-1H-pyrazol-4-yl) methyl] -2,5-dihydro-1H-pyrrole -1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N- (isoxazol-5-ylmethyl) -N-methyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

2 - [{[4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -2,5-dihydro-1H-pyrrol-1-yl] carbonyl} (methyl) amino] ethyl dimethylaminocarboxylate;

2 - [{[4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -2,5-dihydro-1H-pyrrol-1-yl] carbonyl} (methyl) amino] ethyl piperidine-1-carboxylate ;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N- [2- (2-oxopyrrolidin-1-yl) ethyl] -2,5-dihydro-1H-pyrrole-1 β-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N - [(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl) methyl] -2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N- (tetrahydro-2H-pyran-4-ylmethyl) -2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N - {[5- (methoxymethyl) -1H-pyrazol-3-yl] methyl} -N-methyl-2,5-dihydro-1H pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N- (1,3-thiazol-4-ylmethyl) -2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N - [(4-methyl-1,2,5-oxadiazol-3-yl) methyl] -2,5-dihydro -1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N- (1,3-thiazol-2-ylmethyl) -2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N- (isoxazol-3-ylmethyl) -N-methyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N- [2- (1H-1,2,4-triazol-1-yl) ethyl] -2,5-dihydro -1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N- [2- (1H-pyrazol-1-yl) ethyl] -2,5-dihydro-1H-pyrrole-1 β-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N - [(1-methyl-5-oxopyrrolidin-2-yl) methyl] -2,5-dihydro-1H-pyrrole -1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N- (1-isoxazol-3-yl-ethyl) -N-methyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -N- (1,3-dioxolan-2-ylmethyl) -2- (3-hydroxyphenyl) -N-methyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -N- (1,4-dioxan-2-ylmethyl) -2- (3-hydroxyphenyl) -N-methyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N - [(5-methyl-1,3,4-oxodiazol-2-yl) methyl] -2,5-dihydro -1H-pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N- [2- (methylsulfonyl) ethyl] -2,5-dihydro-1H-pyrrole-1-carboxamide;

2 - [{[4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -2,5-dihydro-1H-pyrrol-1-yl] carbonyl} (methyl) amino] ethanesulfonic acid;

2-hydroxyethyl (1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2,2- dimethyl propyl carbamate;

3-hydroxyprolyl (1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2,2- dimethyl propyl carbamate;

2-hydroxyethyl {(1S) -1-isopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethyl} carbamate;

2-hydroxyethyl {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethyl} carbamate;

4-hydroxybutyl (1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2,2- dimethyl propyl carbamate;

(2S) -4- (2,5-difluorophenyl) -1- [2- (methylsulfonyl) ethyl] -2-phenyl-2,5-dihydro-1H-pyrrole;

(2S) -4- (2,5-difluorophenyl) -1- [2- (ethylsulfonyl) ethyl] -2-phenyl-2,5-dihydro-1H-pyrrole;

1 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] pentan-3-one;

4 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] butan-2-one;

4 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -3-methylbutan-2-one;

2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N, N-dimethylethanesulfonamide;

3 - {(2S) -4- (2,5-difluorophenyl) -1- [2- (methylsulfonyl) ethyl] -2,5-dihydro-1H-pyrrol-2-yl} phenol;

methyl 3 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] propanoate;

(2S) -4- (2,5-difluorophenyl) -1- [2- (ethylsulfonyl) propyl] -2-phenyl-2,5-dihydro-1H-pyrrole;

3 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N-methylpropanamide;

3 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N, N-dimethylpropanamide;

3 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -N, N, 2-trimethylpropanamide;

4- {3 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] propanoyl} morpholine;

1- {3 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] propanoyl} -4- (methylsulfonyl) piperazine;

1- {3 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] propanoyl} piperidin-4-ol;

2 - ({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethyl} oxy) -N-ethylacetamide;

4 - ({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethoxy} acetyl) morpholine;

2 - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethoxy } -N- (2-hydroxyethyl) acetamide;

1 - ({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethoxy} acetyl) -4-methylpiperazine;

1 - ({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethoxy} acetyl) piperazine;

2 - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethoxy } -N-piperidin-4-yl-acetamide;

1 - ({((1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethoxy} acetyl) piperidin-4-amine;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -3-morpholin-4-yl-3-oxopropan-1-amine;

N ³ - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2- oxoethyl} -N ¹ , N ¹ -dimethyl-β-alaninamide; and

((1S) -1 - {[(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -2,2-dimethylpropyl) (3-morpholin-4-yl-3-oxopropyl) amine;

or a pharmaceutically acceptable salt or stereoisomer thereof.

12. The compound according to claim 11, selected from the group including

(2S) -4- (2,5-difluorophenyl) -N-methyl-N- (1-methylpiperidin-4-yl) -2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide and

(2S) -4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -1-L-valyl-2,5-dihydro-1H-pyrrole;

or a pharmaceutically acceptable salt or stereoisomer thereof.

13. The compound according to claim 11, is a salt of TFU compounds selected from the group including

4- (2,5-difluorophenyl) -2-phenyl-1-L-prolyl-2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -2-phenyl-1-D-prolyl-2,5-dihydro-1H-pyrrole;

(4R) -4 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} -1,3-triazolidine;

(1S) -1 - {[4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] carbonyl} pentylamine;

4- (2,5-difluorophenyl) -2-phenyl-1 - {[2S, 3S) -2-phenylpyrrolidin-3-yl] carbonyl} -2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -1- (2-methylpropyl) -2-phenyl-2,5-dihydro-1H-pyrrole;

4- (2,5-difluorophenyl) -N-methyl-N - [(1-methylpiperidin-3-yl) methyl] -2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide;

N - {(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoethyl } -2-piperazin-1-ylmethanesulfonamide;

N- (tert-butyl) -2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] acetamide;

(1S) -1-cyclopropyl-2 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] -2-oxoetitl-4- dimethylamino) piperidine-1-carboxylate;

2 - [{[4- (2,5-difluorophenyl) -2 (3-hydroxyphenyl) -2,5-dihydro-1H-pyrrol-1-yl] carbonyl} (methyl) amino] ethyl-4-methylpiperazin-1 β-carboxylate;

4- (2,5-difluorophenyl) -2,5-dihydro-2- (3-hydroxyphenyl) -N-methyl-N- [2- (4-methyl-1-piperazinyl) -2-oxoethyl] -H- pyrrole-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N - {[5- (methoxymethyl) -1H-pyrazol-3-yl] methyl} -N-methyl-2,5-dihydro-1H pyrrol-1-carboxamide;

4- (2,5-difluorophenyl) -2- (3-hydroxyphenyl) -N-methyl-N- (1,3-thiazol-4-ylmethyl) -2,5-dihydro-1H-pyrrol-1-carboxamide;

1- {3 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] propanoyl} piperidin-4-ol and

methyl 3 - [(2S) -4- (2,5-difluorophenyl) -2-phenyl-2,5-dihydro-1H-pyrrol-1-yl] propanoate.

14. A pharmaceutical composition that contains a compound according to claim 1 and a pharmaceutically acceptable carrier.

15. A method for the treatment or prevention of cancer in mammals, if necessary, such therapy, which includes the introduction to the specified mammal a therapeutically effective amount of a compound according to claim 1.

16. The method of treatment or prevention of cancer according to clause 15, where the cancer is selected from cancer of the brain, urogenital tract, lymphatic system, stomach, larynx and lungs.

17. The method of treatment or prevention of cancer according to clause 15, where the cancer is selected from histiocytic lymphoma, adenocarcinoma of the lung, small cell lung cancer, pancreatic cancer, hyoblastoma and breast cancer.

18. The method of treating cancer according to clause 15, which includes the introduction of a therapeutically effective amount of a compound according to claim 1 in combination with radiotherapy.

19. The method of treatment or prevention of cancer according to clause 15, which includes the introduction of a therapeutically effective amount of a compound according to claim 1 in combination with a compound selected from

1) an estrogen receptor modulator,

2) an androgen receptor modulator,

3) a retinoid receptor modulator,

4) a cytotoxic / cytostatic agent,

5) antiproliferative agent,

6) a prenyl protein transferase inhibitor,

7) an HMG-CoA reductase inhibitor,

8) HIV protease inhibitor,

9) reverse transcriptase inhibitor,

10) an angiogenesis inhibitor,

11) PPAR-γ agonists,

12) PPAR-δ agonists,

13) an inhibitor of congenital multidrug resistance,

14) an antiemetic agent,

15) an agent useful in the treatment of anemia,

16) an agent useful in the treatment of neutropenia,

17) an immune-stimulating drug,

18) an inhibitor of cell proliferation and survival signaling, and

19) an agent interfering with control points of the cell cycle.

20. The method of treating cancer according to clause 15, which includes the introduction of a therapeutically effective amount of a compound according to claim 1 in combination with radiotherapy and a compound selected from

1) an estrogen receptor modulator,

2) an androgen receptor modulator,

3) a retinoid receptor modulator,

4) a cytotoxic / cytostatic agent,

5) antiproliferative agent,

6) a prenyl protein transferase inhibitor,

7) an HMG-CoA reductase inhibitor,

8) HIV protease inhibitor,

9) reverse transcriptase inhibitor,

10) an angiogenesis inhibitor,

11) PPAR-γ agonists,

12) PPAR-δ agonists,

13) an inhibitor of congenital multidrug resistance,

14) an antiemetic agent,

15) an agent useful in the treatment of anemia,

16) an agent useful in the treatment of neutropenia,

17) an immune-stimulating drug,

18) an inhibitor of cell proliferation and survival signaling, and

19) an agent interfering with control points of the cell cycle.

21. A method for treating or preventing cancer according to claim 15, which comprises administering a therapeutically effective amount of a compound according to claim 1 and paclitaxel or trastuzumab.

22. A method for treating or preventing cancer according to claim 15, which comprises administering a therapeutically effective amount of a compound according to claim 1 and a GPIIb / IIIa antagonist.

23. A method for treating or preventing cancer according to claim 15, which comprises administering a therapeutically effective amount of a compound according to claim 1 in combination with a proteosome inhibitor.

24. A method for treating or preventing cancer according to claim 15, which comprises administering a therapeutically effective amount of a compound according to claim 1 in combination with an aurora kinase inhibitor.

25. A method for the treatment or prevention of cancer according to claim 15, which comprises administering a therapeutically effective amount of a compound according to claim 1 in combination with a Raf kinase inhibitor.

26. A method of treating or preventing cancer according to claim 15, which comprises administering a therapeutically effective amount of a compound according to claim 1 in combination with a serine / threonine kinase inhibitor.

27. A method for treating or preventing cancer according to claim 15, which comprises administering a therapeutically effective amount of a compound according to claim 1 in combination with a mitotic kinesin inhibitor that is not KSP.

28. A method for modulating the structure of a mitotic spindle, which comprises administering a therapeutically effective amount of a compound according to claim 1.

29. A method of inhibiting mitotic kinesin KSP, which comprises administering a therapeutically effective amount of a compound according to claim 1.